InstalabLoading...
InstalabLoading...
A cortisol breakdown product found in urine that reveals how your liver processes and deactivates your body's primary stress hormone.
When your body releases cortisol in response to stress, illness, or simply waking up in the morning, it does not circulate forever. Your liver breaks cortisol down into inactive fragments that get flushed out through your urine. One of the most abundant of these fragments is 5β-tetrahydrocortisol, commonly abbreviated THF (5β-tetrahydrocortisol). Measuring THF, along with a few related metabolites, gives you a window into how efficiently your liver is clearing cortisol and which specific enzyme pathways are doing the work.
This matters because cortisol metabolism is not the same thing as cortisol production. Two people can produce identical amounts of cortisol yet process it very differently. Shifts in how cortisol is broken down have been linked to metabolic syndrome, insulin resistance, fatty liver, and depression. A standard blood cortisol test captures a snapshot of what is circulating right now. Urinary THF and its companion metabolites capture the cumulative output of your cortisol metabolism over an entire day.
Your liver deactivates cortisol through two parallel routes, each controlled by a different enzyme. One route uses an enzyme called 5β-reductase, and the other uses 5α-reductase. Both enzymes perform the same basic job: they chemically alter cortisol's core ring structure so it can no longer activate the cortisol receptor. The 5β-reductase route produces THF. The 5α-reductase route produces a mirror-image molecule called allo-THF (5α-tetrahydrocortisol).
The distinction between these two routes is not trivial. Research has confirmed that 5β-reduced metabolites like THF genuinely cannot activate the cortisol receptor, meaning 5β-reduction is a true off switch. By contrast, 5α-reduced metabolites retain some ability to activate the receptor. So when your body shifts toward the 5β pathway, it is more completely shutting cortisol down.
A third enzyme in this story is 11β-hydroxysteroid dehydrogenase, or 11β-HSD for short. This enzyme family controls the interconversion between cortisol and its inactive cousin cortisone. The balance between cortisol and cortisone metabolites, reflected in specific urinary ratios, tells you whether your tissues are regenerating active cortisol or letting it stay dormant.
THF is rarely interpreted alone. Its clinical power comes from ratios that compare it with related metabolites. Each ratio illuminates a different piece of the cortisol metabolism puzzle.
The (THF + allo-THF) / THE ratio: THE stands for tetrahydrocortisone, the main breakdown product of cortisone. This ratio reflects the activity of 11β-HSD, the enzyme system that toggles between cortisol and cortisone in your tissues. If this ratio is elevated, it suggests your body is converting more cortisone back into active cortisol. Higher values have been associated with metabolic syndrome, insulin resistance, and impaired insulin-producing cell function. In people with depression, this ratio is also significantly elevated, pointing to altered cortisol handling in that condition.
The THF / allo-THF ratio: This ratio compares the output of the two parallel liver pathways, 5β-reductase versus 5α-reductase. A shift in this ratio can signal dysfunction in one pathway relative to the other. People with depression show a lower allo-THF/THF ratio, suggesting reduced 5α-reductase activity. In a rare condition called apparent mineralocorticoid excess, THF is decreased relative to allo-THF, consistent with a defect in 5β-reductase.
Total glucocorticoid metabolites (THF + allo-THF + THE): Adding all three major metabolites together provides a more comprehensive picture of your total daily cortisol production than urinary free cortisol alone. This sum is particularly informative when evaluating conditions like Cushing's syndrome or metabolic syndrome.
Men and women metabolize cortisol differently. In healthy young adults, women excrete significantly less THF than men (median 1600 vs 2197 μg/day). This reflects genuine sex-based differences in the activity of the liver enzymes that reduce cortisol, not just differences in cortisol production.
In men specifically, increased 5β-reductase activity has been linked to fatty liver. Men with fatty liver show higher urinary excretion of 5β-reduced cortisol and cortisone metabolites and lower cortisol-to-cortisone metabolite ratios. This connection may involve the overlapping role of 5β-reductase in bile acid and cholesterol metabolism, since the same enzyme participates in processing bile acids in the liver.
If your THF levels or related ratios come back elevated, it is worth considering whether metabolic health, particularly liver fat and insulin sensitivity, could be part of the picture. These metabolites are not just abstract chemistry; they connect to conditions you can screen for and act on.
Because THF is a downstream product of cortisol, anything that changes your cortisol production or the activity of your liver's cortisol-processing enzymes will affect your THF level. The research provided focuses on the enzymatic and metabolic determinants rather than specific lifestyle interventions with reported effect sizes, so the following guidance is grounded in those mechanistic findings.
Metabolic health and liver fat: Since enhanced 5β-reductase activity is specifically associated with fatty liver in men, interventions that reduce liver fat, such as weight loss, reduced refined carbohydrate intake, and regular physical activity, may shift 5β-reductase activity and THF output. If you have elevated THF and metabolic syndrome features, addressing insulin resistance is a reasonable priority to discuss with a clinician.
Sex and hormonal context: The significant sex difference in THF excretion means your results should be interpreted against sex-appropriate expectations. Hormonal changes, including those from oral contraceptives or hormone replacement, can influence steroid-metabolizing enzyme activity.
Conditions that alter cortisol production: Any condition that increases cortisol output, such as Cushing's syndrome, chronic high stress, or exogenous glucocorticoid use, will increase the substrate available for THF production and raise total glucocorticoid metabolite levels.